Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CStone Pharmaceuticals ( (HK:2616) ) has issued an update.
CStone Pharmaceuticals said it will present updated clinical data for its internally developed trispecific antibody CS2009 at the ASCO 2026 Annual Meeting, highlighting progress from a global Phase I/II program in non-small cell lung cancer and advanced solid tumors. The company reported strong safety, encouraging efficacy in first-line and later-line NSCLC, signals of activity in colorectal and other “cold” tumors, and is preparing to launch Phase III multi-regional trials, potentially strengthening its position in immuno-oncology and expanding its global registration strategy.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a China-focused biopharmaceutical company specializing in the discovery and development of innovative oncology therapies. Its pipeline includes immuno-oncology assets and targeted drugs aimed at treating solid tumors, with a growing emphasis on advanced biologics such as multispecific antibodies for global markets.
Average Trading Volume: 14,368,076
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.39B
For a thorough assessment of 2616 stock, go to TipRanks’ Stock Analysis page.